ReviewFrontiers in oncology2026
Organoids and AI-integrated models in ovarian cancer research: the future of personalized therapy.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OC) is the deadliest gynecological malignancy which continues to impose a significant challenge in the field of oncology research due to its rapid metastasis, inter and intra-tumor heterogeneity, and treatment resistance. Personalized medicine for OC is still under development where patient-derived organoids (PDO) represent as a promising platform intended towards patient-specific disease modelling, biomarker discovery and therapeutic response assessment. These PDOs generate elaborate, complicated and high dimensional data traversing imaging, advanced omics and pharmacological analyses. Artificial intelligence (AI) and machine learning (ML) approaches allow refined prognostic stratification of patients through improved target delineation and response prediction when integrated with bioinformatics and conventional statistics. This narrative review discusses the foundations laid on the organoid generation and AI-enabled evaluation of ovarian cancer PDOs. The successful translation of AI-guided strategies into clinical oncology will depend on rigorous multi-center validation, harmonized methodologies, and prospective clinical studies demonstrating improvements in patient outcomes and real-world applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.